AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
AgomAb Therapeutics NV American Depositary Shares
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG01ZPFZNN6
9.05▼ 0.21 (-2.27%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
9.26
Day's Range
8.57 – 9.18
52-Week Range
7.92 – 17.82
Volume
46.1K
Avg Volume
132.0K
Share Statistics
Shares Outstanding
Employees
62
Exchange
XNAS
Listed
2026-02-06
Share count as of December 31, 2025

AgomAb Therapeutics NV American Depositary Shares (AGMB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about AgomAb Therapeutics NV American Depositary Shares (AGMB)
What is AgomAb Therapeutics NV American Depositary Shares's Market Cap?
AgomAb Therapeutics NV American Depositary Shares's Market Cap is $309.2M, based on as-reported figures from SEC (XBRL) filings.
What is AgomAb Therapeutics NV American Depositary Shares's Enterprise Value?
AgomAb Therapeutics NV American Depositary Shares's Enterprise Value is $207.8M, based on as-reported figures from SEC (XBRL) filings.
What is AgomAb Therapeutics NV American Depositary Shares's Net Income (TTM)?
AgomAb Therapeutics NV American Depositary Shares's Net Income (TTM) is -$73.4M, based on as-reported figures from SEC (XBRL) filings.
What is AgomAb Therapeutics NV American Depositary Shares's Diluted EPS (TTM)?
AgomAb Therapeutics NV American Depositary Shares's Diluted EPS (TTM) is -2.15, based on as-reported figures from SEC (XBRL) filings.
What is AgomAb Therapeutics NV American Depositary Shares's Net Debt?
AgomAb Therapeutics NV American Depositary Shares's Net Debt is -$101.4M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AGMBAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of EUR, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023
Consolidated statement of profit or loss
Research and development expenses
General and administrative expenses
Total operating expenses
Other operating income
Operating loss
Changes in fair value of financial liabilities
Financial expenses
Financial income
Loss before taxes
Income tax (expense)/income—
Loss for the year
Basic loss per share (in €)
Diluted loss per share (in €)